Skip to content

Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis

Effect of Hyperthyroidism and Its Treatment in Graves' Disease to Early Marker of Atherosclerosis: Review on the Pathway of Insulin Resistance, Lipid, Inflammation, and Endothelial Dysfunction to Pulse Wave Velocity and Carotid Intima-Media Thickness

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05118542
Enrollment
36
Registered
2021-11-12
Start date
2019-01-01
Completion date
2020-08-01
Last updated
2021-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperthyroidism, Graves Disease, Atherosclerosis of Artery, Pathophysiology

Keywords

Hyperthyroidism, Graves Disease, Atherosclerosis, Pathophysiology, Insulin Resistance, Lipid Marker, Inflammatory Marker, PWV, cIMT

Brief summary

During July 2019 to August 2020, a single-blind clinical trial was done to 36 patients with Graves' disease. At the beginning of the study, subjects were accommodated into 2 groups, 17 into PTU groups and 19 into methimazole groups. There were 24 subjects who finished the study, 13 from PTU group and 11 from methimazole group. Blood serum was collected for HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin examination. Meanwhile stiffness and thickness of carotid artery was measured using PWV and cIMT.

Detailed description

This study was a single blind, randomized clinical trial study, conducted in Cipto Mangunkusumo National Referral Hospital from January 2019 to August 2020. We included all adult patient aged 18-65 years with newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month, who agreed to participate in the study. The exclusion criteria was pregnancy, history of coronary heart disease, known malignancy, current use of immunosuppressive medication, sepsis, thyroid crisis, or having allergic reaction to anti-thyroid drugs and other severe side effect. Ethical approval was obtained from the Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia with approval number KET-784/UN.2.F1/ETIK/PPM.00.02/2019. Study participant was observed every month for 3 months. Anti-thyroid drugs (PTU or methimazole) were given according to true simple randomization with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist. At baseline visit, first and third month follow up, blood serum was collected to analyse HOMA-IR, LDL-R, NFĸB, sICAM-1, sVCAM-1 and sE-selectin, meanwhile PWV and cIMT were measured using radiofrequency ultrasound examination of carotid arteries. Categorical data was presented in frequency (%), while numerical data was presented using mean (SD) if normally distributed or median (IQR) if not normally distributed. Correlation Pearson test was performed for normal distributed data and Spearman test for not normal distributed data. To analyze the changes in parameter from baseline, first and third month, repeated ANOVA and General Linear Model test was performed. For not normally distributed data, transformation into normally distributed data was performed and the data was presented as geometric mean (CI 95%).

Interventions

PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.

methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.

Sponsors

Indonesia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Masking description

The care providers gave two choice of drug doses to the research assistant. The research assistant then give the participant their drugs based on the assignment from the randomisation. The investigator and outcome assessor were blinded to the drugs which the participants received

Intervention model description

This study was a single blind, randomized clinical trial study, conducted in Cipto Mangunkusumo National Referral Hospital from January 2019 to August 2020. We included all adult patient aged 18-65 years with newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month, who agreed to participate in the study. The exclusion criteria was pregnancy, history of coronary heart disease, known malignancy, current use of immunosuppressive medication, sepsis, thyroid crisis, or having allergic reaction to anti-thyroid drugs and other severe side effect.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18-65 years * Newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month * Agreed to participate in the study

Exclusion criteria

* Pregnancy * History of coronary heart disease * Known malignancy * Current use of immunosuppressive medication sepsis, thyroid crisis * Having allergic reaction to anti-thyroid drugs and other severe side effect

Design outcomes

Primary

MeasureTime frameDescription
Pulse Wave VelocityChange from Baseline to 3 month follow-upPulse wave velocity was measured using radio frequency ultrasound in supine position at both left and right carotid artery
carotid intima media thicknessChange from Baseline to 3 month follow-upcIMT was measured using radio frequency ultrasound in supine position at both left and right carotid artery

Secondary

MeasureTime frameDescription
NFkBChange from Baseline to 3 month follow-upNFkB was measured from the patient serum using ELISA with Cusabio kit
sICAM-1Change from Baseline to 3 month follow-upsICAM-1 was measured from the patient serum using ELISA with D&G International Inc. kit
HOMA-IRChange from Baseline to 3 month follow-upHOMA-IR was calculated from patient fasting blood glucose and fasting insulin, which both were obtained through serum of the patient. Fasting blood glucose was measured using ECLIA methods with Abbott reagent, while fasting insulin were measured using ELISA with D&G International Inc. kit
sE-selectinChange from Baseline to 3 month follow-upsE-selectin was measured from the patient serum using ELISA with D&G International Inc. kit
sVCAM-1Change from Baseline to 3 month follow-upsVCAM-1 was measured from the patient serum using ELISA with D&G International Inc. kit
LDL-RChange from Baseline to 3 month follow-upLDL-R was measured from the patient serum using ELISA with D&G International Inc. kit

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026